{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:06:06Z","timestamp":1793318766833,"version":"4.5.0"},"reference-count":30,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T00:00:00Z","timestamp":1583107200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Tumori"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Therapeutic decision-making in metastatic castration-resistant prostate cancer (mCRPC) represents an open challenge. Radium-223 is approved for patients with symptomatic bone metastases, no visceral involvement, progressing after at least 2 lines of systemic therapy, or ineligible for any other systemic treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We performed a retrospective, observational study on patients with mCRPC treated with radium-223 at our institution outside of clinical trials, to assess the safety and activity in a real-world population. Data regarding baseline patient\/disease characteristics and treatment outcomes (number of cycles, treatment-related adverse events [AEs], cause of discontinuation, and best response) were collected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Overall, 41 patients were treated from September 2015 to September 2018. Median age was 73 years; baseline Eastern Cooperative Oncology Group Performance Status (ECOG PS) was 0, 1, or 2 in 15%, 80%, and 5% of cases, respectively; and 3%, 41%, 44%, and 12% of patients had &lt;6, 6\u201320, &gt;20, and superscan bone lesions, respectively. A median number of 5 cycles (interquartile range 3\u20136) with median dose 19.52 MBq (interquartile range 12.87\u201324.83) was received. Treatment schedule was completed in 49% of cases; discontinuations due to AEs, disease-related death, or disease progression occurred in 24%, 33%, and 43% of patients, respectively. Any-grade AEs occurred in 73% and grade 3\/4 treatment-related AEs occurred in 29% of patients, mainly anemia, decreased platelet count, and fatigue. No skeletal-related events or treatment-related deaths were recorded. After treatment, 66%, 2%, and 32% of patients had a stable, improved, or deteriorated ECOG PS versus baseline, respectively, and 24%, 61%, and 15% reported a stable, improved, or worsened pain symptom control. Post-treatment versus baseline alkaline phosphatase was reduced or stable in 46% and increased in 54% of patients, whereas prostate-specific antigen was decreased or stable in 83% and increased in 17% of patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Our study provides clinically useful real-world data on radium-223, highlighting the importance of multidisciplinary patient management to guarantee the best continuum of care for patients with mCRPC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/0300891620905646","type":"journal-article","created":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T07:06:15Z","timestamp":1583132775000},"page":"406-412","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["Safety and activity of radium-223 in metastatic castration-resistant prostate cancer: the experience of Istituto Nazionale dei Tumori"],"prefix":"10.1177","volume":"106","author":[{"given":"Alessandra","family":"Raimondi","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierangela","family":"Sepe","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Claps","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Maccauro","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Aliberti","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Pagani","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Apollonio","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Randon","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Peverelli","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ettore","family":"Seregni","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Verzoni","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2498-402X","authenticated-orcid":false,"given":"Giuseppe","family":"Procopio","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,3,2]]},"reference":[{"key":"bibr1-0300891620905646","volume":"41","author":"AIRTUM Working Group","year":"2018","journal-title":"Epidemiol Prev"},{"key":"bibr2-0300891620905646","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra030831"},{"key":"bibr3-0300891620905646","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000521"},{"key":"bibr4-0300891620905646","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040720"},{"key":"bibr5-0300891620905646","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209096"},{"key":"bibr6-0300891620905646","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.07.032"},{"key":"bibr7-0300891620905646","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61389-X"},{"key":"bibr8-0300891620905646","doi-asserted-by":"publisher","DOI":"10.1177\/0300891619851376"},{"key":"bibr9-0300891620905646","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0841"},{"key":"bibr10-0300891620905646","first-page":"3120","volume":"62","author":"Henriksen G","year":"2002","journal-title":"Cancer Res"},{"key":"bibr11-0300891620905646","first-page":"38S","volume":"46","author":"Lewington VJ","year":"2005","journal-title":"J Nucl Med"},{"key":"bibr12-0300891620905646","first-page":"1346","volume":"10","author":"Liepe K","year":"2009","journal-title":"Curr Opin Investig Drugs"},{"key":"bibr13-0300891620905646","doi-asserted-by":"publisher","DOI":"10.1007\/s002590050306"},{"key":"bibr14-0300891620905646","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213755"},{"key":"bibr15-0300891620905646","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30860-X"},{"key":"bibr16-0300891620905646","doi-asserted-by":"publisher","DOI":"10.1177\/1756287216629870"},{"key":"bibr17-0300891620905646","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23286"},{"key":"bibr18-0300891620905646","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2018.10.013"},{"key":"bibr19-0300891620905646","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.12873"},{"key":"bibr20-0300891620905646","doi-asserted-by":"publisher","DOI":"10.1177\/0300891618765571"},{"key":"bibr21-0300891620905646","unstructured":"Bayer. Annex I: summary of product characteristics, ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002653\/WC500156172.pdf (2013, accessed 16 June 2019)."},{"key":"bibr22-0300891620905646","doi-asserted-by":"publisher","DOI":"10.1097\/00002508-198906000-00005"},{"key":"bibr23-0300891620905646","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702"},{"key":"bibr24-0300891620905646","doi-asserted-by":"publisher","DOI":"10.1016\/j.ucl.2017.07.010"},{"key":"bibr25-0300891620905646","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2018.05.003"},{"key":"bibr26-0300891620905646","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-018-4083-3"},{"key":"bibr27-0300891620905646","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2018.06.004"},{"key":"bibr28-0300891620905646","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S122417"},{"key":"bibr29-0300891620905646","unstructured":"Agenzia Italiana del Farmaco. http:\/\/www.agenziafarmaco.gov.it\/content\/nota-informativa-importante-su-xofigo-radio-223-dicloruro-06082018 (2018, accessed 16 June 2019)."},{"key":"bibr30-0300891620905646","unstructured":"European Medicines Agency. Xofigo, ema.europa.eu\/en\/medicines\/human\/EPAR\/xofigo (2018, accessed 16 June 2019)."}],"container-title":["Tumori Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0300891620905646","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0300891620905646","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0300891620905646","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T18:40:04Z","timestamp":1777660804000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0300891620905646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,2]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.1177\/0300891620905646"],"URL":"https:\/\/doi.org\/10.1177\/0300891620905646","relation":{},"ISSN":["0300-8916","2038-2529"],"issn-type":[{"value":"0300-8916","type":"print"},{"value":"2038-2529","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,2]]}}}